Introduction
============

The trace element selenium (Se) is essential for a number of cellular functions. The human selenoproteome has 25 separate genes encoding selenoproteins.^[@bib1]^ These include glutathione peroxidase (*GPX*) family members, including cellular, extracellular, phospholipid hydroperoxide and gastrointestinal GPX. In addition, thioredoxin reductases (TXNRD) also protect tissues from oxidative stress. These proteins are important redox enzymes with a multitude of functions.

The essentiality of Se relates to its incorporation in the amino acid selenocysteine, which is present in the active sites of GPX and other selenoproteins. However, redox-active Se compounds may function both as pro-oxidants and antioxidants depending on species, concentration and the redox state of the cell.^[@bib2],\ [@bib3]^ About half of the Se in whole blood is found in the plasma, of which selenoprotein P (SEPP1) usually constitutes more than 60% and GPX constitutes 25%.^[@bib4]^ SEPP1 contains up to 10 selenocysteine residues and is the means of transporting Se around the body to tissues that need it.^[@bib5]^ It has an antioxidative role in the blood^[@bib6],\ [@bib7]^ and, among other biological effects, it is believed to be active in endothelial protection.^[@bib5]^ In order to obtain the maximum level of SEPP1, an intake of about total 100 μg/day was needed in an adult UK population, meaning that for that population a supplemental intake 50 μg/day, in addition to the habitual intake of \~55 μg/day, was needed.^[@bib8]^

The food intake of Se differs in various parts of the world.^[@bib5]^ This is mainly explained by varying Se content in the soil,^[@bib5]^ although different food habits may have a role.

The soils in North America have a significantly higher content of Se than in Europe;^[@bib5]^ thus, the reported serum Se levels of US citizens are generally above 120 μg/l,^[@bib9],\ [@bib10]^ whereas levels below 90 μg/l have been reported from several European countries.^[@bib11],\ [@bib12],\ [@bib13],\ [@bib14],\ [@bib15]^

The Nordic countries (Finland, Sweden, Norway and Denmark) represent low-Se areas in Europe. In Finland, the reported average intake of Se in the 1970s was 25 μg/day and the reported average plasma Se level was 49.6 μg/l.^[@bib16]^ However, based on the low intake, the authorities in Finland decided to add Se to the fertilizers in 1986.^[@bib17]^ The present average plasma Se level has therefore been raised to about 111 μg/l.^[@bib16]^ In Norway, the import of wheat grains from Northern America has resulted in levels around 90 μg/l in whole blood corresponding to a mean daily intake of about 50 μg/day,^[@bib18]^ which is higher than in Sweden and Denmark.^[@bib19]^

Gao *et al.*^[@bib20]^ reported an average serum Se level of 75.6 μg/l in a population of more than 1900 Swedish persons, indicating a daily intake well below the recommended lower limit. Harris *et al.*^[@bib21]^ reported a very low Se intake of only 24.7 μg/day in a Swedish population in which breast cancer was later diagnosed. Roman Vinas *et al.*^[@bib22]^ reported that between 31% and 47% of an adult and elderly population during 1997--1998 had an intake of Se below the estimated average requirement. These data indicate low Se levels in the Swedish population in general; however, few studies have investigated Se levels nor a possible association between low Se levels and negative health effects. Extended knowledge about this is important for decisions concerning public health.

The aim of the present study was to investigate whether there is still low Se status among elderly Swedes and, furthermore, to analyze whether low Se status is associated with altered mortality in the Swedish population investigated.

Materials and methods
=====================

Participants
------------

The participants in this study were recruited from a rural municipality of 10 300 inhabitants in the south-east of Sweden. All citizens in the municipality aged between 70 and 80 years were invited to participate in the study as part of a continuous epidemiological project in the municipality that had been running since 1998. From a population of 1130 individuals living in the municipality of the chosen age range, 876 individuals agreed to participate and of those 675 agreed to participate in a follow-up project that started in January 2003 and concluded in February 2010.

Of the 675 that consented to participate, 668 agreed that blood samples could be drawn and they were thus included in the present study for analysis of Se at the onset of the study. This population constituted the basal Se measurement population and the population from which mortality was analyzed.

Owing to the fact that 219 participants were randomized to participate in another study, they did not undergo the further risk evaluations of the present study. However, their measured baseline Se levels were used in this study. Thus, the final study population for the current risk evaluation consists of 449 individuals. Out of the 449 individuals, serum samples from 98 subjects were evaluated for Se after 48 months ([Figure 1](#fig1){ref-type="fig"}).

All the participants were examined by one of three experienced cardiologists. A new clinical history was recorded, a clinical examination was performed, Doppler echocardiography and a new electrocardiogram were carried out and the New York Heart Association functional class was assessed. The latter grades how a patient with heart disease experiences symptoms of tiredness, breathlessness or chest pain; it is graded from I to IV, where IV is symptoms already at rest. All-cause and cardiovascular mortalities were registered. The mortality information was obtained from the National Board of Health and Welfare in Sweden, which registers all deaths of Swedish citizens.

The study was approved by the Regional Ethical Committee (diary number 03--176) and conforms to the ethical guidelines of the 1975 Declaration of Helsinki. Written informed consent was obtained from all patients.

Blood samples
-------------

The blood samples were collected while the participants were resting and in a supine position. Pre-chilled EDTA vials were used. The vials were centrifuged at 3000 *g*, +4 °C, plasma was transferred to new vials and was frozen at −70 °C. No samples were thawed until the analyses were carried out.

Se analysis
-----------

The serum Se analyses were performed using inductively coupled plasma mass spectrometry methodology at an Agilent 700 platform at Kompetenzzentrum für komplementärmedizinische Diagnostik, Zweigniederlassung der synlab MVZ Leinfelden GmbH (Leinfelden-Echterdingen, Germany). The accuracy of the measurements was checked by analyzing two external reference materials with certified values of 63 and 103 μg/l (control programme offered by the Society for Advancement of Quality Assurance in Medical Laboratories, INSTAND e.V., Düsseldorf, Germany), showing values within 90%--110% of certified concentrations. A round-robin test with INSTAND e.V. always passed adequately. The precision of the method, checked by repetitive analyses of the same sera, showed an average coefficient of variation of 5.7%.

Echocardiography
----------------

The Doppler echocardiographic examinations (Accuson *XP-128c*, Siemens Healthcare, Siemens AG, Erlangen, Germany) were performed with the participant in the left lateral position. The cardiac function expressed as ejection fraction readings were categorized into four classes, with interclass limits placed at 30%, 40% and 50%.^[@bib23],\ [@bib24]^ Normal systolic function was defined as ejection fraction ≥50%, whereas severely impaired systolic function was defined as ejection fraction *\<*30%.

Statistics
----------

The descriptive data are presented as percentages or mean±s.d. The Student\'s unpaired two-sided *t*-test was used for continuous variables. For variables on the continuous scale level analysis of variance evaluations have been performed, and for variables on the nominal scale level multiple *χ*^2^-tests have been performed. Kaplan--Meier analyses were based on 449 participants illustrating the association between levels of Se and all-cause, and cardiovascular mortality during up to 2500 days. Basal level of Se was analyzed in 668 participants and the values were ordered into quartiles where the first quartile (that is, levels \<57.2 μg/l) was evaluated against the second, third and fourth quartiles. Censored participants were those still living at the end of the study or those who had died for reasons other than all-cause/cardiovascular diseases. Completed participants were those who had died owing to all-cause/cardiovascular diseases.

Risk assessment in the serum Se quartiles was performed using univariate and multivariate Cox proportional hazard regressions. Factors that influence the measured Se levels include certain diseases and smoking. In the multivariate model, adjustments were made for the following clinical variables: male gender, smoking, ischemic heart disease, diabetes, chronic obstructive pulmonary disease and ejection fraction \<40% according to echocardiography.

*P*-values \<0.05 were considered significant, based on two-sided evaluations. All data were analyzed using Statistica v12.0 software (Statsoft Inc., Tulsa, OK, USA).

Results
=======

Population baseline characteristics
-----------------------------------

The characteristics of the study population (*n*=668) divided into the four quartiles of Se are presented in [Table 1](#tbl1){ref-type="table"}. Similar gender (female to male) ratios were found in the different quartiles, except in the fourth quartile. In the first quartile, the group was older and more participants in the third quartile were in the New York Heart Association functional class II. No significant difference was found between the four quartiles with respect to any other variable, including laboratory measures of inflammation.

Serum Se concentrations
-----------------------

At inclusion, the mean serum Se concentration was 67.1 μg/l (s.d. 16.8). The female participants had a concentration of 68.8 μg/l (s.d. 17.8) and the male participants had 65.2 μg/l (s.d. 15.5; *T*=2.8; *P*=0.006) ([Table 2](#tbl2){ref-type="table"}). Serum Se levels were determined again after 48 months in a subset of 98 randomized individuals. In these individuals, the values from the second measurement (for females: 70.8 μg/l in average and for males: 72.5 μg/l in average) showed higher concentrations at the second measurement after 48 months. A detailed analysis of the changes in serum Se concentration is shown in [Table 3](#tbl3){ref-type="table"}.

The current smokers had a lower serum Se concentration (mean 63.1 μg/l; s.d. 17.3) compared with the non-smoking group (mean 67.7 μg/l; s.d. 16.6).

Mortality rates in persons with low versus high Se
--------------------------------------------------

The participants were evaluated regarding possible association between Se level and mortality. Of the 449 participants in the total study population in which the risk evaluations were performed, 122 participants (27.2%) died of all-cause mortality and 85 participants (18.9%) died of cardiovascular mortality during the follow-up period of 2500 days (6.85 years).

A significant difference in mortality rates was found in persons with serum Se values grouped in the lowest Se (first) quartile versus those in the fourth quartiles. In the first quartile, 41 individuals out of 107 died versus 25 out of 111 in the fourth quartile, from all causes combined (*χ*^2^: 6.44; *P*=0.01). Regarding cardiovascular mortality, the same trend was noted: 29/107 in the first quartile and 16/111 in the fourth quartile (*χ*^2^: 5.35; *P*=0.02). An evaluation of the frequency of cancer mortality in the different quartiles of serum Se has also been performed. No difference in cancer mortality was found (data not shown).

A Kaplan--Meier analysis illustrating all-cause ([Figure 2](#fig2){ref-type="fig"}) and cardiovascular mortality ([Figure 3](#fig3){ref-type="fig"}) of the first quartile versus the second-to-fourth quartiles during the follow-up period in the population is shown.

Comparing the first quartile with the second-to-fourth quartiles, a 67% increased risk of all-cause mortality (hazard ratio: 1.67; 95% confidence interval (CI): 1.15--2.44; *P*=0.007) in the univariate Cox proportional hazard regressions analyses was found, and regarding cardiovascular mortality a 73% increased risk (hazard ratio: 1.73; 95% CI: 1.10--2.72; *P*=0.02) was found. Applying a multivariate model where well-known variables influencing risk of mortality as well as serum Se were included, an independent and significantly increased risk of 43% for all-cause mortality and 56% for cardiovascular mortality was found ([Table 4](#tbl4){ref-type="table"}).

Discussion
==========

In the present study, serum Se concentrations from a population of elderly healthy Swedes were low (\~ 67.1 μg/l) compared with the reported Se levels in the United States^[@bib25],\ [@bib26]^ and also relatively low in comparison with values in other regions in Europe.^[@bib18],\ [@bib19],\ [@bib27],\ [@bib28],\ [@bib29],\ [@bib30],\ [@bib31],\ [@bib32]^ The difference in concentrations between smokers and non-smokers in the present study was not significant, which may be an effect of the small size of the smoking group (*n*=40; 9.0%), as some studies have found decreased levels in current smokers.^[@bib33],\ [@bib19]^ However, there are also studies where such an association has not been found.^[@bib34]^

The present Nordic recommendations are 50 μg/day for females and 60 μg/day for males.^[@bib35]^ The serum Se concentrations measured in our study are lower than the values achieved by these recommendations. Thus, a recent Norwegian study indicated that an average dietary intake of 50 μg Se/day resulted in serum levels around 90 μg/l.^[@bib18]^

The most interesting finding in our study was a significantly increased mortality among those in the lowest Se quartile (\<57.2 μg/l). This segment of the population had 43% increased risk for all-cause mortality and 56% increased risk for cardiovascular mortality. As a low Se level could be a result of disease, we therefore evaluated the low Se level and adjusted for well-known clinical conditions that could influence mortality risk. Low Se level was still a significant and independent risk factor for both all-cause and cardiovascular mortality, and the difference in mortality could not obviously be explained by different inflammatory response, as two biomarkers for inflammation did not differ across the four Se quartiles.

Suadacini *et al.*^[@bib36]^ from Denmark showed in a prospective cohort of more than 3000 males that serum Se concentrations below 60 μg/l were associated with increased risk of myocardial infarction. Finnish studies from the 1970s have also observed this association between low serum Se and increased risk of cardiovascular mortality.^[@bib37]^ A study of an elderly French population, referred to as the EVA study, also reported an association between low plasma concentration of Se and increased mortality.^[@bib38]^ In a small study from Spain, Millán Adame *et al.*^[@bib39]^ reported that half of the evaluated population was Se deficient, as their plasma concentration was insufficient for maximal GPX activity, which requires 90 μg/l. Letsiou *et al.*^[@bib13]^ reported in a study on more than 500 individuals from Greece that \>87% of the participants had a lower Se concentration than needed for optimal function of GPX. The same message was reported from the Czech Republic, where a majority of the 3000 blood donors investigated had lower Se concentration than needed for optimal activity of GPX.^[@bib40]^ Finally, in 100 individuals living in Central Poland, a mean serum Se concentration of 51.1 μg/l was reported, which the authors showed was lower than required for cytoprotective gene expression.^[@bib41]^

These observations are also consistent with a meta-analysis of Se and coronary heart disease, which included 25 observational (14 cohort and 11 case--control studies) and six randomized controlled trials.^[@bib42]^ In the meta-analysis, the pooled relative risks between the highest and lowest blood or toenail Se categories were 0.85 (95% CI 0·74--0·99). A higher mean baseline Se intake was found in the six randomized controlled trials mentioned above, compared with our study. However, a more recent meta-analysis of 12 different trials by Rees *et al.*^[@bib43]^ (including the American Selenium and Vitamin E Cancer Prevention Trial (SELECT) and Nutritional Prevention of Cancer (NPC) Trial) could not support the finding that supplementation with Se decreased cardiovascular mortality. It should, however, be noted as mentioned by Hatfield and Gladyshev^[@bib44]^ that both the SELECT and NPC studies included participants with mean plasma Se levels higher than in all European countries (135 and 113 μg/l respectively), and that those two studies comprised the vast majority of participants of the meta-analysis performed by Rees *et al.*^[@bib43]^

Analysis of the participant group with two Se measurements in our study (at inclusion and at 48 months) revealed a statistically significant, but not high, correlation coefficient (*r*=0.34) between the first and the second measurement. This low correlation could be a result of the discussion in the community where the study was performed, resulting in a novel interest in using Se supplementation. Thus, we observed that 63.3% (62 out of 98) had a higher serum Se concentration at the second measurement. The consequence is that results of those assigned to the first quartile may even be underestimated.

From the basal characteristics of the study population ([Table 1](#tbl1){ref-type="table"}), no difference could be found in the concentration of two biomarkers high-sensitivity C-reactive protein and soluble P-selectin between the four quartiles of Se, showing that it is unlikely that the mortality difference result from different levels of inflammation. One possible mechanism for the association between low Se and mortality could be found in the fact that selenoproteins (the GPX family of proteins, TXNRD and SEPP1) have a central role in the defense against oxidative stress, and that increased oxidative stress is reported in patients with ischemic heart disease.^[@bib45],\ [@bib46]^ In heart failure, the balance between cytosolic and mitochondrial reactive oxygen species have been reported to become distorted, leading to oxidative imbalance, mitochondrial dysfunction and eventually to cell death.^[@bib47]^ As an insufficient level of Se will result in only partially functioning anti-oxidative defense, this could explain the increased mortality in the present study among those with low serum Se.

Conclusion
==========

In the present study, serum Se levels in 668 elderly healthy Swedish persons were analyzed. The mean concentration, 67.1 μg/l, is insufficient to achieve optimum function of important selenoproteins.

Significantly increased all-cause mortality and cardiovascular mortality were observed in persons with low serum Se concentrations in an almost 7-year follow-up. The data suggest health benefits from higher Se status. As indicated in our previous report from the same Swedish region,^[@bib48]^ we suggest that Se supplementation should be recommended to persons with serum Se concentration below 57 μg/l.
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![Cumulative proportion surviving from all-cause mortality analyzing serum concentration of Se in the first quartile versus second-to-fourth quartiles. Notes: Censored participants were those still living at the end of the study. Completed participants were those who had died. Persons at risk indicate the number of persons at a specific time point that are exposed to the risk of mortality.](ejcn201592f2){#fig2}

![Cumulative proportion surviving from cardiovascular mortality analyzing serum concentration of Se in the first quartile versus second-to-fourth quartiles. Note: Censored participants were those still living at the end of the study or those who had died due to reasons other than cardiovascular diseases. Completed participants were those who had died due to cardiovascular diseases.](ejcn201592f3){#fig3}

###### Basal characteristics of the study population divided into quartiles of serum Se levels

  *Variables*                     *Quartile 1 \<57.2 μg/l*   *Quartile 2 57.2--67.1 μg/l*   *Quartile 3 67.1--76.1 μg/l*   *Quartile 4 \>76.1 μg/l*  P*-value*
  ------------------------------ -------------------------- ------------------------------ ------------------------------ -------------------------- -----------
  Number of persons                         167                          167                            166                          168              
  Males/females                            87/80                        78/89                          87/79                        67/101            
  Age, years, mean (±s.d.)               78.6 (4.0)                   77.8 (3.8)                     77.3 (3.7)                   77.2 (3.8)         0.01
                                                                                                                                                      
  *History*                                                                                                                                          
   Smoking, *n* (%)                      25 (15.0)                     13 (7.8)                       12 (7.2)                     13 (7.7)          0.05
   Diabetes, *n* (%)                     29 (17.4)                    39 (23.4)                      43 (25.9)                    35 (20.8)          0.27
   Hypertension, *n* (%)                 122 (73.1)                   126 (75.4)                     127 (76.5)                   125 (74.4)         0.90
   COPD, *n* (%)                          15 (9.0)                    23 (13.8)                       16 (9.6)                    26 (15.5)          0.19
   NYHA class I, *n* (%)                 74 (44.3)                    76 (45.5)                      82 (49.4)                    55 (32.7)          \<0.001
   NYHA class II, *n* (%)                47 (28.1)                    56 (33.5)                      46 (27.7)                    55 (32.7)          0.54
   NYHA class III, *n* (%)               38 (22.8)                    30 (18.0)                      37 (22.3)                    26 (15.5)          0.35
   NYHA class IV, *n* (%)                 4 (0.2)                         0                              0                            0               
                                                                                                                                                      
  *Medication*                                                                                                                                       
   ACE inhibitors, *n* (%)               34 (20.4)                    36 (21.6)                      31 (18.7)                    37 (22.0)          0.90
   β-Blockers, *n* (%)                   58 (34.7)                    71 (42.5)                      61 (36.7)                    51 (30.4)          0.11
   Diuretics, *n* (%)                    56 (33.5)                    61 (36.5)                      47 (28.3)                    67 (39.9)          0.15
                                                                                                                                                      
  *Clinical examination*                                                                                                                             
   BP systolic, mm Hg (±s.d.)            148 (23.6)                   150 (23.8)                     147 (23.5)                   151 (22.2)         0.34
   BP diastolic, mm Hg (±s.d.)            75 (9.5)                    76 (11.6)                      74 (11.9)                    75 (12.6)          0.46
   ECG, AF, *n* (%)                      18 (10.8)                    21 (12.6)                       16 (9.6)                     14 (8.3)          0.63
                                                                                                                                                      
  *Lab*                                                                                                                                              
   Hb\<120 g/l, *n* (%)                  28 (16.8)                    19 (11.4)                       16 (9.6)                    19 (11.3)          0.16
   EF\<40%, *n* (%)                       16 (9.6)                     16 (9.6)                      18 (10.8)                     13 (7.7)          0.43
   hs-CRP mg/l (s.d.)                    4.2 (6.5)                    3.0 (3.2)                      3.3 (3.7)                    5.5 (22.0)         0.71
   sP-selectin ng/ml (s.d.)             55.1 (23.4)                  57.7 (25.4)                    59.0 (22.3)                  59.3 (27.4)         0.81

Abbreviations: AF, atrial fibrillation; BP, blood pressure; COPD, chronic obstructive pulmonary disease; ECG, electrocardiogram; EF, ejection fraction from echocardiographic examination; hs-CRP, high-sensitivity analysis of C-reactive protein; NYHA, New York Heart Association functional class; Se, selenium.

*P*-values \<0.05 were considered significant, all *P*-values obtained from analysis of variance evaluation.

###### Serum Se measurement in the study population in two instances

                                                          *Total population*   *Females*      *Males*            P*-value*
  ------------------------------------------------------- -------------------- -------------- ------------- --------------------
  Measurement no. 1, μg/l, mean (±s.d.)                   67.1 (16.8)          68.8 (17.8)    65.2 (15.4)    *T*=2.8; *P*=0.006
  Measurement no. 2 after 48 months, μg/l, mean (±s.d.)   71.6 (24.9)          70.80 (25.9)   72.5 (23.9)    *T*=0.32; *P*=0.75

Abbreviations: Se, selenium; *T*, *T*-statistics.

Measurement no. 1 consisted of 668 individuals. Measurement no. 2 consisted of 98 control individuals from the above population.

###### Change in serum selenium concentration between two measurements during 48 months follow-up

                              *Change in selenium concentration*   *Change in selenium concentration \>30%*   *Change in selenium concentration \>50%*
  -------------------------- ------------------------------------ ------------------------------------------ ------------------------------------------
  Increasing concentration              62/98 (63.3%)                           26/98 (26.5%)                              18/98 (18.4%)
  Decreasing concentration              34/98 (34.7%)                            7/98 (7.1%)                                1/98 (1.0%)
  Unchanged concentration                2/98 (2.0%)                             2/98 (2.0%)                                2/98 (2.0%)

###### Multivariate Cox proportional hazard regression analysis of the relation between low serum Se and various clinical variables in relation to all-cause and cardiovascular mortality in the study population during a follow-up period of 48 months

  *Variables*        *All-cause mortality*    *Cardiovascular mortality*                               
  ------------------ ----------------------- ---------------------------- -------- ------ ------------ --------
  Se Q1\<57.2 μg/l   1.43                             1.02--2.00          0.04     1.56    1.03--2.36  0.04
  Male               1.38                             0.99--1.91          0.06     1.25    0.83--1.88  0.30
  Smoker             1.96                             1.31--2.94          0.001    1.83    1.09--3.08  0.02
  IHD                1.41                             0.81--1.61          0.45     1.30    0.85--1.99  0.22
  Diabetes           1.69                             1.21--2.36          0.002    1.77    1.17--2.68  0.007
  COPD               1.19                             0.77--1.84          0.436    0.88    0.48--1.62  0.68
  EF\<40%            2.12                             1.40--3.22          0.0004   2.40    1.45--3.98  0.0006

Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; EF, ejection fraction; IHD, ischemic heart disease; Q1, first quartile; Se, selenium.

The first quartile of serum Se was evaluated against the second-to-fourth quartiles of Se.
